ALZpathDx Test:
Timely Detection of Alzheimer’s Disease
ALZpathDx assay measures pTau217 in blood, recognized as the earliest and most accurate biomarker for the detection of Alzheimer's disease. We are committed to providing physicians with a reliable tool to aid in the timely diagnosis and management of Alzheimer's disease.
ALZpathDx: Into the Clinic in 2023
ALZpath has established the robust and scalable plasma-based ultra-sensitive assay for the leading blood-based biomarker for Alzheimer’s Disease, pTau217. Over 40,000 tests have been completed worldwide with the ALZpath pTau217 to date, in a research context. The clinical launch of the assay is planned for the second half of 2023, to bring this groundbreaking test to healthcare providers.
ALZpathDx: Accurate, Accessible, Scalable
ALZpathDx was extensively validated and optimized for plasma. We understand the challenges of remote areas and can facilitate blood draws directly or can provide convenient kits that include all necessary materials for blood draw and plasma extraction. Alternatively, you can send us plasma directly. We promptly deliver patient results to the ordering clinician along with a comprehensive explanation of the test.
Bringing ALZpathDx to Your Patients
To partner with us or join our list for the ALZpathDx assay when it becomes available in the second half of 2023, please complete the form below. We look forward to collaborating with you and providing this essential tool for early detection of Alzheimer’s disease.
Publications of Interest
Lilly's Donanemab Significantly Slowed Cognitive and Functional Decline in Phase 3 Study of Early Alzheimer's Disease
Lilly Investors News Release, 2023
Clinical Practice in the Alzheimer’s Biomarker Era – Drugs for the Brain and Care for the Mind
JAMA Network Open, 2023
Alzheimer Disease Biomarkers in Clinical Practice: A Blood-Based Diagnostic Revolution
Journal of Primary Care & Community Health, 2022
Longitudinal plasma p-tau217 is increased in early stages of Alzheimer's disease
Brain, The Journal of Neurology, 2020
